Our Mission

Research Focus

Featured Faculty


Susan Pross, Ph.D.

  • In my role of Director of the Scholarly Concentrations Program I am involved in development and assessment of this elective opportunity for student scholarship and individuation.
  • I am a trained immunologist and microbiologist and did research in the field of immunology for many years. More recently, my focus has changed to education. As such I serve as a Course Director in Year 2 and Director of the Scholarly Concentrations Program (SCP). I am also involved in curriculum development and assessment. I have published and run workshops regarding educational issues and have helped mentor students on educational projects.

Education Programs

Ph.D. Program Master's Program Graduate Certificates Apply Now

Post Docs

  • Our lab is a tumor immunology lab that focuses on investigating signaling pathways that contributes to defects in immune responses in pancreatic cancer.
  • My project researches the role of the Ikaros transcription factor in regulating effector and regulatory T cell homeostasis in a mouse model of pancreatic cancer.

Ph.D. Students

  • My current research focuses on understanding the role of the Amyloid Precursor Protein (APP) in pancreatic cancer. It is well known that pancreatic cancer has a poor prognosis and very low 5-year survival rates. Early detection poses a challenge mainly owing to the location of this organ and a non-symptomatic progression. At the molecular level, the oncogene RAS is known to be mutated and overexpressed in this cancer and the signaling pathways are somewhat understood. Using several pancreatic cancer cells lines, our recent findings show that APP is overexpressed in most pancreatic cancer cells lines as well. Preliminary studies have shown that APP can regulate RAS transcription levels and knock down of APP can inhibit RAS protein expression. Using this information, my project aims to understand the mechanism of regulation of RAS by APP and to establish APP, its processed fragments, and associated signaling pathways as possible targets for drug development against pancreatic cancer.